Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Fennec Pharmaceuticals Inc (FRX.TO)

Fennec Pharmaceuticals Inc (FRX.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 373,166
  • Shares Outstanding, K 27,100
  • Annual Sales, $ 21,252 K
  • Annual Income, $ -16,045 K
  • 60-Month Beta 0.92
  • Price/Sales 12.46
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade FRX.TO with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.60
  • Most Recent Earnings $-0.10 on N/A
  • Latest Earnings Date 05/09/24
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.05
  • Number of Estimates 2
  • High Estimate -0.03
  • Low Estimate -0.07
  • Prior Year -0.31
  • Growth Rate Est. (year over year) +83.87%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.81 +0.08%
on 04/19/24
15.20 -15.66%
on 03/25/24
-0.36 (-2.73%)
since 03/15/24
3-Month
12.02 +6.66%
on 02/20/24
15.20 -15.66%
on 03/25/24
-1.40 (-9.85%)
since 01/09/24
52-Week
9.27 +38.30%
on 10/06/23
15.43 -16.92%
on 12/28/23
+1.52 (+13.45%)
since 04/14/23

Most Recent Stories

More News
Stocks in play: Fennec Pharmaceuticals Inc.

Reported its financial results for the fiscal year ended December 31, 2023. Net losses for the fourth ...

FRX.TO : 12.82 (-6.90%)
Stocks in play: Fennec Pharmaceuticals Inc.

Will release its full-year and fourth-quarter 2023 financial results before the opening of the U.S. ...

FRX.TO : 12.82 (-6.90%)
Stocks in play: Fennec Pharmaceuticals Inc.

Will release its first-quarter 2023 financial results before the opening of the U.S. financial markets ...

FRX.TO : 12.82 (-6.90%)
Stocks in play: Fennec Pharmaceuticals Inc.

Today reported its financial results for the fiscal year ended December 31, 2022. Net losses for the ...

FRX.TO : 12.82 (-6.90%)
Stocks in play: Fennec Pharmaceuticals Inc

Announced that the U.S. Food and Drug Administration has granted Orphan Drug Exclusivity to PEDMARK® ...

FRX.TO : 12.82 (-6.90%)
Stocks in play: Fennec Pharmaceuticals Inc.

Reported its financial results for the fiscal quarter ended September 30. Net loss for the three months ...

FRX.TO : 12.82 (-6.90%)
Stocks in play: Fennec Pharmaceuticals Inc

Today announced the U.S. commercial launch and availability of PEDMARK® (sodium thiosulfate injection) ...

FRX.TO : 12.82 (-6.90%)
Stocks in play: Fennec Pharmaceuticals Inc

Today announced that the U.S. Food and Drug Administration has approved PEDMARK®, a sodium thiosulfate ...

FRX.TO : 12.82 (-6.90%)
Fennec Pharmaceuticals Announces Up to $45 Million Investment From Petrichor

~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to be Funded Upon Potential FDA Approval of...

FRX.TO : 12.82 (-6.90%)
FENC : 9.32 (-2.61%)
Fennec Announces Results of Annual Meeting

RESEARCH TRIANGLE PARK, N.C., June 14, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that...

FENC : 9.32 (-2.61%)
FRX.TO : 12.82 (-6.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Key Turning Points

3rd Resistance Point 13.77
2nd Resistance Point 13.77
1st Resistance Point 13.77
Last Price 12.82
1st Support Level 13.77
2nd Support Level 13.77
3rd Support Level 13.77

See More

52-Week High 15.43
Fibonacci 61.8% 13.08
Last Price 12.82
Fibonacci 50% 12.35
Fibonacci 38.2% 11.62
52-Week Low 9.27

See More

Business Summary

Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar